China Preclinical Cro Market Size & Outlook, 2023-2030
China preclinical cro market, 2018-2030 (US$M)
Related Markets
China preclinical cro market highlights
- The China preclinical cro market generated a revenue of USD 292.8 million in 2023 and is expected to reach USD 654.3 million by 2030.
- The China market is expected to grow at a CAGR of 12.2% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2023 | USD 292.8 million |
| Market revenue in 2030 | USD 654.3 million |
| Growth rate | 12.2% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, China accounted for 5.1% of the global preclinical cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 654.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China preclinical cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to preclinical cro market will help companies and investors design strategic landscapes.
Toxicology testing was the largest segment with a revenue share of 22.58% in 2023. Horizon Databook has segmented the China preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the lucrative preclinical trial markets owing to its skilled professionals, cost efficiency, and growing pharmaceutical industry. The country has witnessed positive growth in global preclinical trials conducted in 2023 and is expected to grow at a significant rate over the forecast period. The primary reason for outsourcing preclinical services in China is the higher cost efficiency provided by Chinese CROs as compared to the U.S. and Europe.
Most of life sciences companies outsource their preclinical trials to China due to higher cost efficiency. These advantages are expected to contribute to the growth of preclinical trials outsourcing in the country. However, quality issues and lack of standardization in preclinical trials conducted in this region may limit the market growth over the forecast period.
Reasons to subscribe to China preclinical cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China preclinical cro market databook
-
Our clientele includes a mix of preclinical cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China preclinical cro market , including forecasts for subscribers. This country databook contains high-level insights into China preclinical cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China preclinical cro market size, by service, 2018-2030 (US$M)
China Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
